Jackson, Grant Investment Advisers, Inc. Avadel Pharmaceuticals PLC Transaction History

Jackson, Grant Investment Advisers, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 23, 2019	SELL	$1.74 - $4.66 $435 - $1,165	-250 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$4.08 - $7.14 $1,020 - $1,785	250 New	250 $1,000
Q2 2018 Aug 02, 2018	SELL	$5.89 - $7.78 $1,472 - $1,945	-250 Closed	0 $0
Q4 2017 Feb 01, 2018	SELL	$8.03 - $11.25 $2,007 - $2,812	-250 Reduced 50.0%	250 $2,000
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $4,175 - $5,250	500	500 $5,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Jackson, Grant Investment Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Jackson, Grant Investment Advisers, Inc. with notifications on news.